Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6723473 | 0.93 | KDM4E (0.51) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL15922800 | 0.90 | SMN1; SMN2 (0.57) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL12744387 | 0.87 | POLB (0.58) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL1456869 | 0.87 | KDM4E (0.52) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL14850947 | 0.86 | ALDH1A1 (0.56) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL3961147 | 0.86 | MAPT (0.57) | EGFRHTTMAPK1ALDH1A1KDM4E | |
| SCHEMBL203833 | 0.85 | POLB (0.60) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL15923112 | 0.85 | MAPK1 (0.52) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL15923117 | 0.85 | MAPK1 (0.52) | EGFRCHRM2CHRM1DRD2ADRA2B | |
| SCHEMBL213486 | 0.84 | POLB (0.56) | EGFRCHRM2CHRM1DRD2ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915281-B2 | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-29 | — | — | US | disclosed |
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287725-A1 | Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method | IFNG, IL4, IL2 | EGFR 4040/4885CHRM2 3887/4885CHRM1 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.